Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWU0I2)

Drug Name

Pralsetinib Drug Info

Synonyms

GBLBJPZSROAGMF-SIYOEGHHSA-N; Blu667; 2097132-94-8; SCHEMBL18806610; SCHEMBL18789229; SCHEMBL18789228; GTPL10033; BLU-668; EX-A1944; HY-112301; CS-0044766; N-[(1S)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-[4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]cyclohexane-1-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

Cross-matching ID

PubChem CID: 129073603
CAS Number: CAS 2097132-94-8
TTD Drug ID: DMWU0I2
ACDINA Drug ID: D01355

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Proto-oncogene c-Ret (RET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[3]
Regorafenib	DMHSY1I	Gastrointestinal stromal tumour	2B5B	Approved	[4]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Selpercatinib	DMZR15V	Non-small-cell lung cancer	2C25.Y	Approved	[6]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[7]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[8]
GSK3179106	DM2KCIP	Inflammatory bowel disease	DD72	Phase 1	[9]
BOS172738	DM9L0D8	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Ret (RET)	TT4DXQT	RET_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
8	Clinical pipeline report, company report or official report of Turning Point Therapeutics.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	National Cancer Institute Drug Dictionary (drug name Zeteletinib).